about.jpg

publication 3

Out of 331 organizations in 42 countries around the world, Design House, which is one of NilePreneurs’ initiatives by Nile University, has been selected by NASA as one of the few international companies who will have the license to manufacture its new pneumatic ventilator device “VITAL” for treating COVID-19 patients.

Out of 331 organizations in 42 countries around the world, Design House, which is one of NilePreneurs’ initiatives by Nile University, has been selected by NASA as one of the few international companies who will have the license to manufacture its new pneumatic ventilator device “VITAL” for treating COVID-19 patients. NilePreneurs is a national, fast-growing, initiative funded by the Central Bank of Egypt, and implemented by Nile University.

NilePreneurs aims to enhance the ecosystem for entrepreneurs in Egypt through its different programs. The initiative works closely with different banks, governmental entities and international organizations to achieve its targets. It developed a set of services for SMEs and Startups; as of 2019, their services are summarized under the following four groups: Business Development Services, Incubation, Training for Growth, Innovation Support. Representing the only licensed manufacturer from Africa and one of only two manufacturers from the Arab World and MENA, NilePreneurs has proven its distinction as one of the top international startups in Egypt.

To understand more the gravity of NASA’s choice, it’s important to grasp the size and concept of the “VITAL” project; VITAL is an abbreviation for Ventilator Intervention Technology Accessible Locally, which is a device that will combat the currents COVID-19 global crisis. NASA's Jet Propulsion Laboratory (JPL) is helping the world during the current COVID-19 pandemic with innovation, space technology and engineering. JPL is designing an FDA qualifiable ventilating device that can serve a targeted subset of the patient population suffering from Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.